 MONMOUTH JUNCTION, N.J., Nov. 03, 2020 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010LYTENAVATM NORSE THREE. Patient enrollment for the study was completed in less than one month, significantly ahead of the planned four-month enrollment schedule. 